These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2312764)
21. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776 [TBL] [Abstract][Full Text] [Related]
22. [Relations between pharmacokinetics and effectiveness of ACE inhibitors]. Rettig R; Gohlke P; Unger T Z Kardiol; 1991; 80 Suppl 2():16-20. PubMed ID: 2024539 [TBL] [Abstract][Full Text] [Related]
23. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. Stangier J; Schmid J; Türck D; Switek H; Verhagen A; Peeters PA; van Marle SP; Tamminga WJ; Sollie FA; Jonkman JH J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1312-22. PubMed ID: 11185629 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs. Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Rakhit A; Kochak GM; Tipnis V; Hurley ME Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. Stangier J; Su CA; Roth W J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323 [TBL] [Abstract][Full Text] [Related]
27. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses. Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935 [TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics of benazepril relative to other ACE inhibitors. Gengo FM; Brady E Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Onoyama K; Nanishi F; Okuda S; Oh Y; Fujishima M; Tateno M; Omae T Clin Pharmacol Ther; 1988 Mar; 43(3):242-9. PubMed ID: 3345615 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers. Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094 [TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure. Till AE; Dickstein K; Aarsland T; Gomez HJ; Gregg H; Hichens M Br J Clin Pharmacol; 1989 Feb; 27(2):199-204. PubMed ID: 2540786 [TBL] [Abstract][Full Text] [Related]
32. Disposition and safety of omapatrilat in subjects with renal impairment. Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407 [TBL] [Abstract][Full Text] [Related]
33. Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects. Davies BE; Coates PE; Clarke JG; Thawley AR; Sutton JA Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):70-3. PubMed ID: 3872847 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate. Lefebvre HP; Jeunesse E; Laroute V; Toutain PL J Vet Intern Med; 2006; 20(3):499-507. PubMed ID: 16734081 [TBL] [Abstract][Full Text] [Related]
35. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. Aronoff G; Brier M; Mayer ML; Barbalas M; Aogaichi K; Sloan R; Brazzell R; Massarella J J Clin Pharmacol; 1991 Jan; 31(1):38-44. PubMed ID: 2045527 [TBL] [Abstract][Full Text] [Related]
36. The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment. Begg EJ; Bailey RR; Lynn KL; Robson RA; Frank GJ; Olson SC J Hypertens Suppl; 1989 Sep; 7(5):S29-32. PubMed ID: 2681603 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of intravenous cilazaprilat in normal volunteers. Whitehead EM; Walters GE; Williams PE; Johnston GD Br J Clin Pharmacol; 1989 Jun; 27(6):873-5. PubMed ID: 2757899 [TBL] [Abstract][Full Text] [Related]
39. Oral pharmacokinetics and pharmacodynamics of idrapril calcium, the prototype of a new class of angiotensin converting enzyme inhibitors, in humans. Criscuoli M; Subissi A; Coppini A; Capone P; Taddei S; Salvetti A J Hypertens Suppl; 1993 Dec; 11(5):S340-1. PubMed ID: 8158413 [No Abstract] [Full Text] [Related]
40. Disposition of fosinopril sodium in healthy subjects. Singhvi SM; Duchin KL; Morrison RA; Willard DA; Everett DW; Frantz M Br J Clin Pharmacol; 1988 Jan; 25(1):9-15. PubMed ID: 2967089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]